ABSTRACT
Objective To evaluate the utilization patterns, effectiveness, and patient satisfaction of telehealth services among individuals with hypertension and/or diabetes, and to investigate the influence of social determinants of health (SDOH) on telehealth access and utilization in this population.
Methods We conducted a cross-sectional analysis using data from the 2022 Health Information National Trends Survey (HINTS 6) by the National Cancer Institute. The study sample included 3,009 respondents with self-reported diabetes, hypertension, or both conditions. Telehealth usage was assessed through 14 survey questions, and participant characteristics were analyzed using sociodemographic, baseline health, and SDOH data.
Results Of the 6,252 HINTS 6 survey respondents, 3,009 met the inclusion criteria. Significant sociodemographic differences were observed across the diabetes and/or hypertension groups. No significant differences were found in telehealth usage among the groups, with 43.9% of respondents utilizing telehealth in the past year. Common reasons for telehealth use included provider recommendation, convenience, and infection avoidance. Social determinants of health, such as food insecurity and transportation issues, were more prevalent among individuals with both conditions, though no significant differences in telehealth experiences were noted across groups.
Conclusion Telehealth shows potential for managing chronic conditions like hypertension and diabetes, demonstrating substantial adoption and universal accessibility. However, disparities influenced by SDOH highlight the need for targeted interventions to ensure equitable access. Addressing privacy concerns, leveraging healthcare providers’ recommendations, and tackling SDOH barriers are crucial for fostering wider telehealth adoption and improving outcomes. Future research should focus on the long-term impacts of telehealth and further investigate SDOH factors to develop tailored interventions that enhance engagement and equitable access across diverse patient populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Cancer Institute: https://hints.cancer.gov/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
